Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
Uutela A, Osterlund E, Halonen P, Kallio R, Ålgars A, Salminen T, Lamminmäki A, Soveri LM, Ristamäki R, Lehtomäki K, Stedt H, Heervä E, Muhonen T, Kononen J, Nordin A, Ovissi A, Kytölä S, Keinänen M, Sundström J, Nieminen L, Mäkinen MJ, Kuopio T, Ristimäki A, Isoniemi H, Osterlund P.
Uutela A, et al. Among authors: makinen mj.
Br J Cancer. 2022 Sep;127(4):686-694. doi: 10.1038/s41416-022-01858-8. Epub 2022 May 24.
Br J Cancer. 2022.
PMID: 35610367
Free PMC article.
Clinical Trial.